Cancer Letters
Volume 243, Issue 2 , Pages 235-245, 18 November 2006

Biochemical basis of 4-hydroxyanisole induced cell toxicity towards B16-F0 melanoma cells

Department of Pharmaceutical Sciences, School of Pharmacy, and Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, 1300 Coulter Drive, Amarillo, TX, 79106, USA

Received 20 August 2005; received in revised form 6 October 2005; accepted 27 November 2005.

Abstract 

In the current work we investigated for the first time the biochemical basis of 4-hydroxyanisole (4-HA) induced toxicity in B16-F0 melanoma cells. It was found that dicoumarol, a diaphorase inhibitor, and 1-bromoheptane, a GSH depleting agent, increased 4-HA induced toxicity towards B16-F0 cells whereas dithiothreitol, a thiol containing agent, and ascorbic acid (AA), a reducing agent, largely prevented 4-HA toxicity. TEMPOL and pyrogallol, free radical scavengers, did not significantly prevent 4-HA toxicity towards B16-F0 cells. GSH>AA>NADH prevented the o-quinone formation when 4-HA was metabolized by tyrosinase/O2. 4-HA metabolism by horseradish peroxidase/H2O2 was prevented more effectively by AA than NADH>GSH. We therefore concluded that quinone formation was the major pathway for 4-HA induced toxicity in B16-F0 melanoma cells whereas free radical formation played a negligible role in the 4-HA induced toxicity.

Keywords: 4-Hydroxyanisole, Tyrosinase, Melanoma, B16, B16-F0, Anticancer drugs, Cancer, Alkoxyphenols, Phenol, Catechols, Toxicity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(05)01039-6

doi:10.1016/j.canlet.2005.11.046

Cancer Letters
Volume 243, Issue 2 , Pages 235-245, 18 November 2006